TSH Biopharm Corp. Ltd.(TW:8432)
NT$61.90+0.40 (+0.65%)
TW:8432
TSH Biopharm Corp. Ltd. financials statements
NT$61.90
At close:+0.40 (+0.65%)
TSH Biopharm Corp. Ltd. (8432) Ratios
TSH Biopharm Corp. Ltd. Ratios
TW:8432's free cash flow for Q2 2026 was NT$50.67M. For the 2026 fiscal year, TW:8432's free cash flow was decreased by NT$-299.00K and operating cash flow was NT$50.97M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.27 | 6.25 | 8.33 | 5.56 | 10.72 |
| Quick Ratio | 5.58 | 5.40 | 7.45 | 5.04 | 9.87 |
| Cash Ratio | 2.05 | 2.82 | 4.31 | 2.38 | 4.45 |
| Solvency Ratio | 0.71 | 0.65 | 0.63 | 0.37 | 0.66 |
| Operating Cash Flow Ratio | 0.68 | 0.88 | 0.25 | 0.17 | 0.80 |
| Short-Term Operating Cash Flow Coverage | 19.86 | 11.12 | 75.95 | 0.87 | 155.80 |
| Net Current Asset Value | NT$ 1.19B | NT$ 1.09B | NT$ 980.13M | NT$ 920.45M | NT$ 834.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.01 | 0.04 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.01 | 0.06 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.01 | 0.05 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Financial Leverage Ratio | 1.35 | 1.32 | 1.26 | 1.26 | 1.08 |
| Debt Service Coverage Ratio | 23.06 | 9.63 | 77.81 | 2.19 | 109.16 |
| Interest Coverage Ratio | 273.99 | 374.16 | 92.49 | 121.57 | 769.11 |
| Debt to Market Cap | 0.00 | 0.01 | 0.00 | 0.03 | 0.00 |
| Interest Debt Per Share | 0.53 | 0.97 | 0.22 | 1.68 | 0.13 |
| Net Debt to EBITDA | -1.79 | -2.72 | -5.72 | -4.11 | -5.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 49.17% | 52.23% | 49.31% | 52.61% | 59.82% |
| EBIT Margin | 16.34% | 15.59% | 9.47% | 11.06% | 14.90% |
| EBITDA Margin | 18.34% | 18.18% | 12.25% | 13.96% | 17.25% |
| Operating Profit Margin | 16.34% | 15.29% | 7.85% | 11.47% | 14.88% |
| Pretax Profit Margin | 17.57% | 15.54% | 9.38% | 10.96% | 14.89% |
| Net Profit Margin | 10.42% | 10.14% | 7.64% | 8.35% | 11.39% |
| Continuous Operations Profit Margin | 14.05% | 12.02% | 8.01% | 8.93% | 11.39% |
| Net Income Per EBT | 59.31% | 65.21% | 81.47% | 76.18% | 76.54% |
| EBT Per EBIT | 107.52% | 101.65% | 119.58% | 95.60% | 100.03% |
| Return on Assets (ROA) | 7.14% | 6.14% | 4.43% | 4.31% | 4.03% |
| Return on Equity (ROE) | 9.65% | 8.13% | 5.60% | 5.45% | 4.35% |
| Return on Capital Employed (ROCE) | 12.66% | 10.45% | 5.03% | 6.91% | 5.68% |
| Return on Invested Capital (ROIC) | 10.02% | 7.95% | 4.26% | 5.42% | 4.33% |
| Return on Tangible Assets | 8.38% | 7.28% | 4.60% | 4.51% | 4.04% |
| Earnings Yield | 4.60% | 4.80% | 3.18% | 3.39% | 2.76% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.25 | 5.22 | 3.85 | 3.63 | 4.17 |
| Payables Turnover | 16.64 | 9.72 | 7.99 | 6.17 | 13.53 |
| Inventory Turnover | 4.36 | 3.03 | 3.47 | 3.27 | 2.27 |
| Fixed Asset Turnover | 31.20 | 27.61 | 24.82 | 17.80 | 15.11 |
| Asset Turnover | 0.68 | 0.61 | 0.58 | 0.52 | 0.35 |
| Working Capital Turnover Ratio | 1.17 | 1.07 | 0.85 | 0.84 | 0.49 |
| Cash Conversion Cycle | 147.68 | 153.01 | 154.21 | 153.13 | 221.35 |
| Days of Sales Outstanding | 85.94 | 69.96 | 94.74 | 100.66 | 87.45 |
| Days of Inventory Outstanding | 83.67 | 120.59 | 105.14 | 111.61 | 160.87 |
| Days of Payables Outstanding | 21.94 | 37.55 | 45.67 | 59.14 | 26.98 |
| Operating Cycle | 169.61 | 190.55 | 199.87 | 212.27 | 248.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.99 | 4.79 | 0.88 | 0.89 | 1.79 |
| Free Cash Flow Per Share | 2.90 | 4.71 | 0.74 | 0.41 | 1.78 |
| Dividend Paid and CapEx Coverage Ratio | 1.80 | 3.54 | 0.51 | 0.45 | 0.99 |
| Capital Expenditure Coverage Ratio | 34.26 | 67.00 | 6.10 | 1.83 | 179.86 |
| Operating Cash Flow Coverage Ratio | 5.86 | 4.97 | 4.32 | 0.54 | 13.72 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.16 | 0.04 | 0.05 | 0.17 |
| Free Cash Flow Yield | 4.97% | 7.69% | 1.45% | 0.86% | 4.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.12 | 20.85 | 31.49 | 29.53 | 36.18 |
| Price-to-Sales (P/S) Ratio | 2.26 | 2.11 | 2.40 | 2.46 | 4.12 |
| Price-to-Book (P/B) Ratio | 2.10 | 1.69 | 1.76 | 1.61 | 1.57 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 20.14 | 13.00 | 68.82 | 116.87 | 24.94 |
| Price-to-Operating Cash Flow Ratio | 19.55 | 12.81 | 57.53 | 53.15 | 24.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.69 | 0.25 | 0.00 | 0.96 | -1.56 |
| Enterprise Value Multiple | 10.56 | 8.89 | 13.89 | 13.54 | 18.61 |
| Enterprise Value | 2.59B | 1.80B | 1.38B | 1.40B | 1.33B |
| EV to EBITDA | 10.56 | 8.89 | 13.89 | 13.54 | 18.61 |
| EV to Sales | 1.94 | 1.62 | 1.70 | 1.89 | 3.21 |
| EV to Free Cash Flow | 17.22 | 9.96 | 48.73 | 89.66 | 19.43 |
| EV to Operating Cash Flow | 16.72 | 9.81 | 40.74 | 40.78 | 19.32 |
| Tangible Book Value Per Share | 27.60 | 34.78 | 31.55 | 29.91 | 28.20 |
| Shareholders’ Equity Per Share | 27.88 | 36.25 | 28.82 | 29.58 | 28.29 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | 0.23 | 0.15 | 0.19 | 0.23 |
| Revenue Per Share | 25.83 | 29.06 | 21.10 | 19.30 | 10.80 |
| Net Income Per Share | 2.69 | 2.95 | 1.61 | 1.61 | 1.23 |
| Tax Burden | 0.59 | 0.65 | 0.81 | 0.76 | 0.77 |
| Interest Burden | 1.08 | 1.00 | 0.99 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.02 | 0.03 | 0.03 | 0.04 | 0.06 |
| SG&A to Revenue | 0.33 | 0.34 | 0.39 | 0.39 | 0.41 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.11 | 1.06 | 0.55 | 0.42 | 1.46 |
Currency in TWD
